Action 0MGB GENMAB A/S
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Genmab A/S London S.E.

Actions

0MGB

DK0010272202

Temps réel estimé Cboe Europe
Autres places de cotation
 17:00:00 03/07/2024 		Varia. 5j. Varia. 1 janv.
1 742 DKK +1,99% Graphique intraday de Genmab A/S -3,93% -19,25%
28/06 L'autorisation du traitement du lymphome de Genmab et AbbVie recommandée dans l'UE MT
28/06 AbbVie et Genmab reçoivent un avis positif de l'Europe sur l'autorisation de mise sur le marché d'un éventuel traitement du lymphome MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Ambu A/S: Un líder innovador en equipos médicos de un solo uso
Genmab A/S - Epcoritamab Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed, Refractory Follicular Lymphoma
Genmab A/S - Completion of Share Buy-back Program
Would you like some more inflation?
Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU
AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
AbbVie Receives Positive CHMP Opinion for Epcoritamab for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
Bolsa de Madrid: ¿Le apetece un poco más de inflación?
Genmab Closes DKK3.5 Billion Share Buyback Early
Completion of Share Buy-back Program
Genmab A/S - EPKINLY Approved by U.S. FDA for Patients with Relapsed or Refractory Follicular Lymphoma
AbbVie - U.S. Food and Drug Administration Grants Second Approval for EPKINLY to Treat Patients with Relapsed or Refractory Follicular Lymphoma
Genmab Gets FDA Approval for Follicular Lymphoma Treatment
Genmab Wins US Approval for Follicular Lymphoma Treatment
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY
U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action GMAB
  4. Action 0MGB
  5. Actualités Genmab A/S
  6. Autres langues